Page 140 - TD-3-4

Tumor Discovery CTC characterization for EGFR mutations

doi: 10.1016/j.snb.2012.11.060 56. Heitzer E, Auer M, Gasch C, et al. Complex tumor
genomes inferred from single circulating tumor cells by
45. Tsuji K, Hayata Y. Riken Cell Bank; 1989. Available from:
https://www.cellbank.brc@rike.jp/rcb4455.pc9 [Last array-CGH and next-generation sequencing. Cancer Res.
2013;73(10):2965-2975.
accessed on 2024 May 22].
doi: 10.1158/0008-5472.CAN-12-4140
46. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of
mutations in EGFR in circulating lung-cancer cells. N Engl J 57. Evans M, O’Sullivan B, Smith M, et al. Large-scale EGFR
Med. 2008;359(4):366-377. mutation testing in clinical practice: Analysis of a series of
18,920 Non-small cell lung cancer cases. Pathol Oncol Res.
doi: 10.1056/NEJMoa0800668
2019;25(4):1401-1409.
47. Ju S, Chen C, Zhang J, et al. Detection of circulating
tumor cells: Opportunities and challenges. Biomark Res. doi: 10.1007/s12253-018-0460-2
2022;10(1):58. 58. Martin J, Lehmann A, Klauschen F, et al. Clinical impact of
rare and compound mutations of epidermal growth factor
doi: 10.1186/s40364-022-00403-2
receptor in patients with non-small-cell lung cancer. Clin
48. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of Lung Cancer. 2019;20(5):350-362.e4.
EGFR mutation in patients with non-small cell lung
cancer: A systematic review and meta-analysis. Oncotarget. doi: 10.1016/j.cllc.2019.04.012
2016;7(48):78985-78993. 59. Marchetti A, Del Grammastro M, Felicioni L, et al.
Assessment of EGFR mutations in circulating tumor cell
doi: 10.18632/oncotarget.12587
preparations from NSCLC patients by next generation
49. Graham RP, Treece AL, Lindeman NI, et al. Worldwide sequencing: Toward a real-time liquid biopsy for treatment.
frequency of commonly detected EGFR mutations. Arch PLoS One. 2014;9(8):e103883.
Pathol Lab Med. 2018;142(2):163-167.
doi: 10.1371/journal.pone.0103883
doi: 10.5858/arpa.2016-0579-cp
60. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations
50. Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to in the epidermal growth factor receptor underlying
clinical implementation. Mol Oncol. 2021;15(6):1617-1621. responsiveness of non-small-cell lung cancer to gefitinib.
doi: 10.1002/1878-0261.12997 N Engl J Med. 2004;350(21):2129-2139.
51. Midha A, Dearden S, McCormack R. EGFR mutation doi: 10.1056/NEJMoa040938
incidence in non-small-cell lung cancer of adenocarcinoma 61. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung
histology: A systematic review and global map by ethnicity cancer - molecular and clinical predictors of outcome.
(mutMapII). Am J Cancer Res. 2015;5(9):2892-2911. N Engl J Med. 2005;353(2):133-144.
52. Mao L, Zhao W, Li X, et al. Mutation spectrum of EGFR from doi: 10.1056/NEJMoa050736
21,324 Chinese patients with non-small cell lung cancer 62. González Manzano R, Martínez Navarro E, Eugenieva E,
(NSCLC) successfully tested by multiple methods in a CAP- Fernandez Morejon FJ, Farre J, Brugaralos A. A novel
accredited laboratory. Pathol Oncol Res. 2021;27:602726.
EGFR nonsense mutation in a non-small-cell lung cancer
doi: 10.3389/pore.2021.602726 (NSCLC) patient who did not derive any clinical benefit
with combination chemotherapy and erlotinib. Clin Transl
53. Petrackova A, Vasinek M, Sedlarikova L, et al. Standardization
of sequencing coverage depth in NGS: Recommendation Oncol. 2008;10(7):442-444.
for detection of clonal and subclonal mutations in cancer doi: 10.1007/s12094-008-0229-2
diagnostics. Front Oncol. 2019;9:851.
63. Fu M, Zhang W, Shan L, et al. Mutation status of somatic
doi: 10.3389/fonc.2019.00851 EGFR and KRAS genes in Chinese patients with prostate
cancer (PCa). Virchows Arch. 2014;464(5):575-581.
54. Singh RR. Next-generation sequencing in high-sensitive
detection of mutations in tumours: Challenges, advances, doi: 10.1007/s00428-014-1566-x
and applications. J Mol Diagn. 2020;22(8):994-1007.
64. Kim H, Kim BH, Lee D, Shin E. Genomic alterations in
doi: 10.1016/j.jmoldx.2020.04.213 signet ring and mucinous patterned colorectal carcinoma.
Pathol Res Pract. 2019;215(10):152566.
55. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for
validation of next-generation sequencing-based oncology doi: 10.1016/j.prp.2019.152566
panels: A joint consensus recommendation of the 65. Tanaka Y, Terai Y, Tanabe A, et al. Prognostic effect of
association for molecular pathology and college of American epidermal growth factor receptor gene mutations and the
Pathologist. J Mol Diagn. 2017;19(3):341-365.
aberrant phosphorylation of Akt and ERK in ovarian cancer.
doi: 10.1016/j.jmoldx.2017.01.011 Cancer Biol Ther. 2011;11(1):50-57.

Volume 3 Issue 4 (2024) 16 doi: 10.36922/td.3987